These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 16566935)

  • 1. Does the serum E2 level change following coasting treatment strategy to prevent ovarian hyperstimulation syndrome impact cycle outcomes during controlled ovarian hyperstimulation and in vitro fertilization procedure?
    Yumuşak ÖH; Kahyaoğlu S; Özgü Erdinç AS; Yılmaz S; Engin Üstün Y; Yılmaz N
    Turk J Obstet Gynecol; 2014 Sep; 11(3):159-164. PubMed ID: 28913010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Coasting on Intracytoplasmic Sperm Injection Outcome in Antagonist and Agonist Cycle.
    İltemir Duvan ZC; Namlı Kalem M; Onaran Y; Aktepe Keskin E; Ayrım A; Pekel A; Kafalı H; Turhan N
    Int J Fertil Steril; 2017; 11(1):1-6. PubMed ID: 28367298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
    Tehraninejad ES; Nasiri R; Rashidi B; Haghollahi F; Ataie M
    Arch Gynecol Obstet; 2010 Sep; 282(3):319-25. PubMed ID: 20379731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of coasting in patients undergoing controlled ovarian stimulation with the gonadotropin-releasing hormone antagonist cetrorelix.
    Bahceci M; Ulug U; Tosun S; Erden HF; Bayazit N
    Fertil Steril; 2006 May; 85(5):1523-5. PubMed ID: 16566935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety aspects of gonadotrophin-releasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born.
    Ludwig M; Katalinic A; Felberbaum RE; Diedrich K
    Reprod Biomed Online; 2002; 5 Suppl 1():61-7. PubMed ID: 12537784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Coasting and ovarian stimulation protocols in high-responder patients undergoing assisted conception].
    Merviel P; Claeys C; Héraud MH; Lourdel E; Lanta S; Barbier F; Nasreddine A
    Gynecol Obstet Fertil; 2005 Sep; 33(9):703-12. PubMed ID: 16129645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
    Olivennes F
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.